Clinica di Ematologia AOU Ospedali Riuniti di Ancona Ancona Italy

Clinica Ematologica e Unità di Terapie Cellulari Azienda Sanitaria Universitaria Friuli Centrale Università di Udine Udine Italy

Department of Emergency and Organ Transplantation ''Aldo Moro'' University School of Medicine Bari Italy

Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic

Department of Hematology Erasmus MC Cancer Institute Rotterdam the Netherlands

Department of Medicine Azienda Sanitaria Locale Torino 4 Cirié Chivasso e Ivrea Italy

Division of Hematology AOU Policlinico University of Catania Catania Italy

Division of Hematology Department of Human Pathology in Adulthood and Childhood University of Messina 98122 Messina Italy

Division of Hematology Department of Translational Medicine University of Eastern Piedmont 28100 Novara Italy

Division of Hematology IRCCS Casa Sollievo della Sofferenza Hospital San Giovanni Rotondo Italy

Divisione di Ematologia Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Università degli Studi di Milano Milano Italy

Ematologia Ospedale San Luigi Gonzaga Orbassano Italy

Faculty of Medicine University of Ostrava Ostrava Czech Republic

Hematology Azienda Ospedaliero Universitaria and Department of Medicine and Surgery University of Parma Parma Italy

Hematology Department of Translational and Precision Medicine Azienda Ospedaliera Policlinico Umberto 1 Sapienza University of Rome Rome Italy

Hematology St Eugenio Hospital ASL Roma 2 Tor Vergata University Rome Italy

Myeloma Unit Division of Hematology University of Torino Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino Torino Italy

Padova University School of Medicine Hematology and Clinical Immunology Padova Italy

SC di Ematologia e CTMO Ospedale Oncologico di Riferimento Regionale A Businco ARNAS G Brozu Cagliari Italy

SC Hematology AO Città della Salute e della Scienza Turin Italy

Unit of Hematology and Stem Cell Transplantation AOUC Policlinico Bari Italy

Università degli Studi di Perugia Azienda Ospedaliera Santa Maria Terni Italy

Zobrazit více v PubMed

Larocca A, et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) Leukemia. 2018;32:1697–1712. doi: 10.1038/s41375-018-0142-9. PubMed DOI

Salvini M, D’Agostino M, Bonello F, Boccadoro M, Bringhen S. Determining treatment intensity in elderly patients with multiple myeloma. Expert Rev. Anticancer Ther. 2018;18:917–930. doi: 10.1080/14737140.2018.1496823. PubMed DOI

Palumbo A, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068–2074. doi: 10.1182/blood-2014-12-615187. PubMed DOI PMC

Bringhen S, et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica. 2020;105:1937–1947. doi: 10.3324/haematol.2019.226407. PubMed DOI PMC

Larocca A, et al. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. Leukemia. 2016;30:1320–1326. doi: 10.1038/leu.2016.36. PubMed DOI

Bringhen S, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124:63–69. doi: 10.1182/blood-2014-03-563759. PubMed DOI

Bringhen S, et al. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: a pooled analysis. Crit. Rev. Oncol. Hematol. 2018;130:27–35. doi: 10.1016/j.critrevonc.2018.07.003. PubMed DOI

United Nations - Department of Economic and Social Affairs - Popular Division. World Population Ageing 2019 (ST/ESA/SER.A/444) (United Nations, New York, 2020).

Mina R, Bringhen S, Wildes TM, Zweegman S, Rosko AE. Approach to the Older Adult With Multiple Myeloma. Am. Soc. Clin. Oncol. Educ. B. 2019;39:500–518. doi: 10.1200/EDBK_239067. PubMed DOI PMC

Larocca, A. et al. Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients. Blood.10.1182/blood.2020009507. Online ahead of print (2021). PubMed

Stege, C. A. M. et al. Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study. Blood. Vol. 134, Abstract #695 [ASH 2019 61st Meeting] (2019).

The EHA Research Roadmap: Malignant Lymphoid Diseases